Literature DB >> 17899574

The left portal vein as an indicator of watershed in the fetal circulation: development during the second half of pregnancy and a suggested method of evaluation.

J Kessler1, S Rasmussen, T Kiserud.   

Abstract

OBJECTIVES: The left portal vein represents a watershed area in the fetal circulation and the change of flow direction is a suggested marker of circulatory compromise. Our aim was to study the left portal vein of uncompromised human pregnancies and establish reference ranges.
METHODS: One hundred and sixty low-risk pregnant women were recruited to a longitudinal study that included four to five Doppler measurements at monthly intervals during the second half of pregnancy.
RESULTS: Based on 554 Doppler recordings we found time-averaged maximum flow velocities increasing from a mean of 10.6 cm/s to 14.2 cm/s during 21-31 weeks of gestation, remaining stable until 37 weeks and decreasing towards term. Intermittent flow reversal occurred during fetal respiratory movements, and continuous flow reversal was seen in 2/160 fetuses close to delivery.
CONCLUSIONS: We propose time-averaged maximum blood velocity measurement for quantification of the watershed phenomenon in the left portal branch, and have provided reference ranges for single observations and serial measurements. Copyright (c) 2007 ISUOG

Entities:  

Mesh:

Year:  2007        PMID: 17899574     DOI: 10.1002/uog.5146

Source DB:  PubMed          Journal:  Ultrasound Obstet Gynecol        ISSN: 0960-7692            Impact factor:   7.299


  2 in total

1.  Altered development of fetal liver perfusion in pregnancies with pregestational diabetes.

Authors:  Agnethe Lund; Cathrine Ebbing; Svein Rasmussen; Torvid Kiserud; Mark Hanson; Jörg Kessler
Journal:  PLoS One       Date:  2019-03-13       Impact factor: 3.240

2.  Pre-gestational diabetes: Maternal body mass index and gestational weight gain are associated with augmented umbilical venous flow, fetal liver perfusion, and thus birthweight.

Authors:  Agnethe Lund; Cathrine Ebbing; Svein Rasmussen; Elisabeth Qvigstad; Torvid Kiserud; Jörg Kessler
Journal:  PLoS One       Date:  2021-08-16       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.